8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report (Aug 4, 2004)

Filed August 4, 2004For Securities:ALNY

Summary

This Form 8-K filing by Alnylam Pharmaceuticals, Inc. on August 4, 2004, primarily serves to announce the company's financial results for the quarter ended June 30, 2004. While the filing itself is brief and points to an attached press release (Exhibit 99.1) for the detailed financial information, it marks a reporting event for investors to review the company's performance during that period. Investors should refer to the furnished press release for specifics on revenue, expenses, net income/loss, and any significant operational developments. The significance for investors lies in understanding Alnylam's financial standing and operational progress as of mid-2004. This update is crucial for assessing the company's trajectory, particularly in the context of its research and development activities in the pharmaceutical sector, and for making informed investment decisions. The disclaimer regarding the information not being deemed "filed" for certain SEC provisions is standard for such earnings release disclosures.

Key Highlights

  • 1Announcement of Q2 2004 financial results on August 4, 2004.
  • 2Detailed financial results are available in the press release furnished as Exhibit 99.1.
  • 3The filing is a routine disclosure of operational and financial condition.
  • 4Alnylam Pharmaceuticals, Inc. is the reporting entity.
  • 5The report covers the quarterly period ending June 30, 2004.
  • 6Standard disclaimer provided regarding the 'filed' status of the furnished information.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce Alnylam Pharmaceuticals, Inc.'s financial results for the quarterly period ended June 30, 2004. The detailed financial information is provided in a separate press release, Exhibit 99.1.

The actual financial numbers and details for the quarter ended June 30, 2004, are located in the press release furnished as Exhibit 99.1 to this Form 8-K. Investors should consult that exhibit for specific financial data.

The disclaimer means that, for certain legal purposes under the Securities Exchange Act of 1934 (like Section 18 liability), the information furnished in this 8-K (specifically the press release) is not considered 'filed' with the SEC. This is a common practice for earnings releases and does not prevent the information from being relevant for investment analysis, but it changes its legal standing under specific sections of the act.